This six-week project addresses a critical need for new treatments for diffuse midline glioma (DMG), the second most common type of high-grade brain tumour in children.

The prognosis is extremely poor, with an average survival of just 12 months. This project aims to find a new therapy combination to be used with radiotherapy to directly improve outcomes for these patients.